Health Topics — Pain & Inflammation
Living with Chronic Pain
For the person whose pain has become the background of daily life — what the research on CBG, CBD, and the body's own pain-regulating systems has examined.
Chronic pain changes the shape of a day. It changes what you plan, what you avoid, how far you're willing to walk, how much you're willing to commit to. It changes how you sleep and how you wake. For many people it has been present for so long that they've stopped expecting to be without it — they manage it, work around it, and occasionally hope for something that actually addresses it rather than just taking the edge off.
If you're reading this, you probably know what that managing feels like from the inside. And you're probably looking for honest information rather than promises.
Chronic pain is not the same as acute pain, and treating it as though it is — with interventions designed for short-term pain events — is one reason so many people find conventional management inadequate. Acute pain is a signal: something is wrong, attend to it. Chronic pain has often outlasted its original cause. It has, in many cases, become self-sustaining — a pain system that has been sensitized by prolonged input until it responds to signals that wouldn't have registered as painful before.
This is not imaginary pain. It is a documented change in how the nervous system processes signals — what researchers call central sensitization. The threshold for pain lowers. Normal sensory input begins to register as painful. The pain is real, measurable, and distinct from the original injury or condition that started it. Understanding this distinction matters — because a pain that has become self-sustaining needs a different approach than a pain that is responding to ongoing damage.
The body's own pain-regulating systems
The endocannabinoid system is present throughout the nervous system structures involved in pain processing — in the spinal cord, in the brain regions that modulate how pain signals are interpreted, and in peripheral tissues where pain originates. CB1 receptors in the spinal cord play a documented role in moderating the transmission of pain signals upward to the brain. CB2 receptors in peripheral tissue are involved in regulating the inflammation that often underlies chronic pain conditions.
In plain terms: the body has its own system for turning down pain signals, and the endocannabinoid system is part of how it does that. When this system is functioning well, pain signals are modulated — the body's response is proportionate to the actual input. In chronic pain states, research suggests that endocannabinoid tone may be reduced — which would mean less of the body's own modulating capacity is available at exactly the time it is most needed.
Inflammation is the other half of this picture for many chronic pain sufferers. Persistent low-grade inflammation — in joints, in soft tissue, in the nervous system itself — is both a driver of pain and a consequence of it. The inflammatory signaling pathways that CBG has been shown to interact with in preclinical research are the same pathways that sustain this kind of inflammation. This is mechanistic evidence — laboratory findings, not human trials — but the pathways are real and documented.
What the research on CBG and CBD has examined
CBD has some of its strongest human research evidence in pain — specifically neuropathic pain and pain associated with multiple sclerosis. These are not the same as general chronic pain, and we don't present them as equivalent. But the evidence that CBD interacts meaningfully with pain-relevant biological systems in human beings is more developed here than in most domains.
CBG's pain research is preclinical. In animal models and laboratory settings, CBG has shown interactions with TRPV1 receptors — involved in pain signal transmission — and with the inflammatory signaling pathways, including NF-κB and PPAR-γ, that drive persistent inflammation in chronic pain conditions. CBG also acts on CB2 receptors, which are present in peripheral inflammatory tissue and which the body appears to upregulate in chronic pain states — as if reaching for more of what the condition has depleted. These are real and documented mechanisms. They are not clinical outcomes in pain patients.
What CBD and CBG appear to do together, in the research, is cover more of the relevant territory than either does alone — CBD with its human evidence in pain and its interaction with the endocannabinoid tone, CBG with its multi-mechanism anti-inflammatory preclinical profile. This is the rationale for whole-plant preparations: not that the combination is proven to work better, but that the biological case for why it might is more complete than the case for either compound alone.
On the evidence — and on chronic pain specifically
The pain research described here is genuine and the mechanisms are documented. No human trial has tested CBG for chronic pain. CBD's strongest human pain evidence is in neuropathic pain specifically — not in all chronic pain contexts. We present this research in that proportion.
Chronic pain is a serious medical condition that warrants clinical assessment and management. The research context here is relevant to understanding the evidence base — it is not a substitute for appropriate clinical care.
What this means in practice
We can't tell you a CBG or CBD preparation will reduce your pain. The research doesn't support that claim and we don't make it. What the research does support is a biological picture of why cannabinoids interact with pain-relevant systems — and that picture is more complete and more plausible than the one behind many interventions that get less scrutiny.
The preparations we make are whole-plant — the full botanical range of the hemp plant preserved through traditional alcohol maceration and slow-heat oil infusion. We grow what we prepare. Every batch is independently tested. If you are considering a CBG or CBD preparation alongside whatever else you are doing to manage your pain, the research context here is the honest frame for that consideration.
People who use whole-plant cannabinoid preparations for pain typically find that consistency matters significantly — that the effect, if any, requires sustained use rather than acute intervention. This is consistent with how the endocannabinoid system's regulatory function works, and consistent with how anti-inflammatory support works generally. It is a different model than a pain reliever — and that distinction is worth being clear about before starting.
Future articles in this pillar will examine joint pain and inflammation specifically, what happens when the pain system becomes self-sustaining, and the research on topical cannabinoid applications for localized pain. The research section has the fuller mechanism picture now if you want to go deeper.
Chronic pain is not a failure to manage well. It is a documented change in how the nervous system processes signals — and a condition that the body's own regulatory systems, including the endocannabinoid system, are directly involved in. The cannabinoid pain research is genuine, unevenly developed across pain types, and worth understanding honestly. We will follow it and update this article as the evidence develops. In the meantime, you deserve accurate information and a source that gives it to you plainly.
These statements have not been evaluated by the Food and Drug Administration. J.P. Hemp Company products are not intended to diagnose, treat, cure, or prevent any disease.